Collegium Pharmaceutical (NASDAQ:COLL) Downgraded by StockNews.com to Buy

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday.

Other equities research analysts also recently issued reports about the stock. Truist Financial boosted their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. HC Wainwright raised their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Trading Down 0.7 %

Shares of COLL opened at $36.19 on Wednesday. The company has a market capitalization of $1.18 billion, a PE ratio of 15.08 and a beta of 0.94. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11. Collegium Pharmaceutical has a fifty-two week low of $20.95 and a fifty-two week high of $42.29. The stock has a fifty day moving average of $37.66 and a two-hundred day moving average of $35.38.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The company had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. During the same quarter last year, the firm posted $1.13 earnings per share. Collegium Pharmaceutical’s revenue was up 7.2% on a year-over-year basis. As a group, analysts forecast that Collegium Pharmaceutical will post 5.79 EPS for the current year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of COLL. Pacer Advisors Inc. increased its stake in Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after purchasing an additional 821,541 shares in the last quarter. Rubric Capital Management LP grew its position in Collegium Pharmaceutical by 27.2% during the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after purchasing an additional 499,473 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after acquiring an additional 17,942 shares during the last quarter. Principal Financial Group Inc. increased its position in Collegium Pharmaceutical by 8.2% in the 2nd quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock worth $54,124,000 after purchasing an additional 128,003 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Collegium Pharmaceutical by 8.0% during the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after acquiring an additional 113,300 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.